Candel Therapeutics, Inc.
CADL
$12.17
-$0.43-3.41%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 64.78% | 56.32% | 42.19% | 40.60% | 16.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 139.29% | 100.30% | 94.38% | 50.82% | 30.40% |
| Operating Income | -139.29% | -100.30% | -94.38% | -50.82% | -30.40% |
| Income Before Tax | -711.20% | -220.08% | -109.59% | -5.85% | 78.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -711.20% | -220.08% | -109.59% | -5.85% | 78.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -711.20% | -220.08% | -109.59% | -5.85% | 78.43% |
| EBIT | -139.29% | -100.30% | -94.38% | -50.82% | -30.40% |
| EBITDA | -143.03% | -104.63% | -98.37% | -52.87% | -31.40% |
| EPS Basic | -463.69% | -197.20% | -35.78% | 38.26% | 87.49% |
| Normalized Basic EPS | -463.57% | -197.16% | -36.13% | 38.26% | 87.49% |
| EPS Diluted | -463.69% | -209.31% | -35.78% | 38.26% | 87.49% |
| Normalized Diluted EPS | -463.57% | -205.46% | -36.13% | 38.26% | 87.49% |
| Average Basic Shares Outstanding | 43.97% | 23.53% | 54.36% | 71.47% | 72.33% |
| Average Diluted Shares Outstanding | 43.97% | 13.87% | 54.36% | 71.47% | 72.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |